Publications
See a complete PubMed list of publications by Shlomo Melmed, MB, ChB.
- Ben-Shlomo A, Deng N, Ding E, Yamamoto M, Mamelak A, Chesnokova V, Labadzhyan A, Melmed S. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. J Clin Invest. 2020 Nov 2;130(11):5738-5755
- Chesnokova V, Melmed S. Peptide hormone regulation of DNA damage responses. Endocr Rev. 2020 Jul 1;41(4):519-537
- Melmed S. Pituitary-tumor endocrinopathies. N Engl J Med. 2020 Mar 5;382(10):937-950.
- Melmed S. Pathogenesis and diagnosis of growth hormone deficiency in adults. N Engl J Med. 2019 Jun 27;380(26):2551-2562.
- Melmed S. New therapeutic agents for acromegaly. Nat Rev Endocrinol. 2016 Feb;12(2):90-98.
- Chesnokova V, Zonis S, Zhou C, Recouvreaux MV, Ben-Shlomo A, Araki T, Barrett R, Workman M, Wawrowsky K, Ljubimov VA, Uhart M, Melmed S. Growth hormone is permissive for neoplastic colon growth. Proc Natl Acad Sci USA. 2016 Jun;113(23):E32590-32599.
- Liu NA, Araki T, Cuevas-Ramos D, Hong J, Ben-Shlomo A, Tone Y, Tone M, Melmed S. Cyclin E-mediated human proopiomelanocortin regulation as a therapeutic target for Cushing disease. J Clin Endocrinol Metab. 2015;100(7):2557-2564.
- Zhou C, Jiao Y, Wang R, Ren SG, Wawrowsky K, Melmed S. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion. J Clin Invest. 2015;125(4):1692-1702.
- Melmed S, Popovic V, Bidlingmaier M, Mercado M, van der Lely AJ, Biermasz N, Bolanowski M, Coculescu M, Schopohl J, Racz K, et al. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter Phase III trial. J Clin Endocrinol Metab. 2015;100(4):1699-1708.
- Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S. A structural and functional acromegaly classification. J Clin Endocrinol Metab. 2015;100(1):122-131.
- Melmed S, Kleinberg DL, Bonert V, Fleseriu M. Acromegaly: assessing the disorder and navigating therapeutic options for treatment. Endocr Pract. 2014 Oct;20 Suppl 1:7-17; quiz 18-20.
- Ben-Shlomo A, Mirocha J, Gwin SM, Khine AK, Liu NA, Sheinin RC, Melmed S. Clinical factors associated with biochemical adrenal-cortisol insufficiency in hospitalized patients. Am J Med. 2014;127(8):754-762.
- Eigler T, Ben-Shlomo A, Zhou C, Khalafi R, Ren SG, Melmed S. Constitutive somatostatin receptor subtype-3 signaling suppresses growth hormone synthesis. Mol Endocrinol. 2014;28(4):554-564.
- Chesnokova V, Zhou C, Zonis S, Tani Y, Ben-Shlomo A, Ren SG, Melmed S. Growth hormone is a cellular senescence target in pituitary and non-pituitary cells. Proc Natl Acad Sci USA. 2013 Aug;110(35):E3331-3339.
- Fukuoka H, Cooper O, Ben-Shlomo A, Mamelak A, Ren SG, Bruyette D, Melmed S. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest. 2011 Dec;121(12):4712-4721.
- Liu NA, Jiang H, Ben-Shlomo A, Wawrowsky K, Fan XM, Lin S, Melmed S. Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci USA. 2011 May 17;1808(20):8414-8419.
- Melmed S. Acromegaly pathogenesis and treatment. J Clin Invest. 2009 Nov;119(11):3189-3202.
- Ben-Shlomo A, Schmid H, Wawrowsky K, Pichurin O, Hubina E, Chesnokova V, Liu NA, Culler M, Melmed S. Differential ligand-mediated pituitary somatostatin receptor subtype signaling: implications for corticotroph tumor therapy. J Clin Endocrinol Metab. 2009 Nov;94(11):4342-4350.
Contact the Melmed Lab
8700 Beverly Blvd.
Davis Building, Room 3024
Los Angeles, CA 90048